Daniel G. Chain, Ph.D.
Chief Executive Officer and Chairman
Dr. Chain was a founder and joined the company in October 2005 as Chairman and CEO. Dr. Chain was previously President and CEO of Mindset Biopharmaceuticals, (USA) Inc., which he founded in 1998 and continues to serve as its President. Dr. Chain is the inventor of Intellect's ANTISENILIN® monoclonal antibody that relates to the Company's platform technology for the prevention and treatment of Alzheimer's disease. Dr. Chain obtained his B.Sc. in Biochemistry from the Institute of Biology in London and obtained his Ph.D. in Biochemistry from the Weizmann Institute of Science in Israel. He trained as a post-doctoral research fellow at the Center for Neurobiology and Behavior at Columbia University in New York during which Dr. Chain's work focused on research the molecular basis of long term memory.

Elliot M. Maza
President and Chief Financial Officer
Elliot M. Maza, J.D., C.P.A., joined Intellect in May 2006 as Executive Vice President and Chief Financial Officer. Prior to joining Intellect, Mr. Maza was Chief Financial Officer of Emisphere Technologies, Inc., a NASDAQ listed biopharmaceutical company specializing in oral drug delivery. He was previously a partner at Ernst and Young LLP and a Vice President at Goldman Sachs, Inc. and JP Morgan Securities, Inc. Mr. Maza practiced law at Sullivan and Cromwell in New York. Mr. Maza serves on the Board of Directors and is Chairman of the Audit Committee of Tapestry Pharmaceuticals, Inc., a NASDAQ listed, development stage company focused on developing proprietary therapies for the treatment of cancer. Mr. Maza received his J.D. degree from the University of Pennsylvania Law School in 1985 and is a licensed C.P.A. in the States of New Jersey and New York.